Actively Recruiting
Open-label Study of Zigakibart Injections for Adults With IgA Nephropathy to Assess Kidney Disease Markers and Function
Led by Novartis Pharmaceuticals · Updated on 2026-10-21
32
Participants Needed
30
Research Sites
14 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of zigakibart on the progression of Immunoglobulin A Nephropathy IgAN, a kidney disease. This open-label, multicenter study involves adult participants with IgAN who are randomized into two groups differing only by the timing of an on-treatment kidney biopsy, either at the end of the first or second year of treatment. The study is sponsored by Novartis Pharmaceuticals and aims to assess kidney disease markers and dysfunction over time. Participants receive zigakibart as 600 mg subcutaneous injections every two weeks for up to two years 104 weeks. The total participation period may last up to 125 weeks, including an 8-week screening, the 104-week treatment period, and a 13-week safety follow-up. The study measures changes in kidney tissue IgA deposits, protein levels in urine, kidney function, and immune markers among others. Throughout the study, participants will undergo regular evaluations including kidney biopsies, blood and urine tests, and monitoring of side effects. Researchers will track changes in various disease and immune markers at multiple time points during and after treatment. Safety is closely monitored during the 13-week follow-up after treatment ends. The total commitment for participants can last nearly two and a half years.
CONDITIONS
Brief Title
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here